Products
Ravulizumab Biosimilar Monoclonal Antibody (Complement C5) for Research
Pre-Made Ravulizumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It is designed to bind to and prevent the activation of Complement component 5 (C5).
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-472-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Ravulizumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody |
| INN Name | Ravulizumab |
| Target | CO5 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 5i5k:HL:XY |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Alexion Pharmaceuticals |
| Conditions Approved | Paroxysmal nocturnal haemoglobinuria |
| Conditions Active | Haemolytic uraemic syndrome;Myasthenia gravis;IgA nephropathy |
| Conditions Discontinued | na |
| Development Tech | na |
About target - C5
1. Protein Complement C5
2. Gene C5
3. Organism Homo sapiens (Human)
Function
Dipeptidase that hydrolyzes cystinyl-bis-glycine. Does not hydrolyze leukotriene D4 (LTD4) into leukotriene E4 (LTE4).
Catalytic activity
an L-aminoacyl-L-amino acid + H2O = 2 an L-α-amino acid
EC:3.4.13.19
Source: Rhea.
2 H2O + L-cystine-bis-glycine = 2 glycine + L-cystine
Source: Rhea.
Cofactor
Zn2+
Activity regulation
Inhibited by L-penicillamine.
